Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro

Experimental Hematology

Volumn 39, Issue 7, 2011, Pages 773-783.e1

  Tucci, Marco ^a   Ciavarella, Sabino ^a   Strippoli, Sabino ^a   Brunetti, Oronzo ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ARTICLE; CELL CLONING; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL TRANSFORMATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

EID: 79960598123     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.04.006     Document Type: Article

References (36)

1. Mundy G.R. Myeloma bone disease. Eur J Cancer 1998, 34:246-251.
2. Chauhan D., Singh A.V., Brahmandam M., et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009, 16:309-323.
3. Fayette J., Durand I., Bridon J.M., et al. Dendritic cells enhance the differentiation of naive B cells into plasma cells in vitro. Scand J Immunol 1998, 48:563-570.
4. Kukreja A., Hutchinson A., Dhodapkar K., et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006, 203:1859-1865.
5. Kukreja A., Radfar S., Sun B.H., Insogna K., Dhodapkar M.V. Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009, 114:3413-3421.
6. Rendtlew Danielsen J.M., Knudsen L.M., Dahl I.M., Lodahl M., Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 2007, 138:756-760.
7. Rivollier A., Mazzorana M., Tebib J., et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.
8. Nakashima T., Takayanagi H. Osteoclasts and the immune system. J Bone Miner Metab 2009, 27:519-529.
9. Schiano de Colella J.M., Barbarat B., Sweet R., et al. ligand stimulation induces a partial but functional maturation of human monocyte-derived dendritic cells. Eur Cytokine Netw 2008, 19:81-88.
10. Wang J., Loberg R., Taichman R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006, 25:573-587.
11. Zannettino A.C., Farrugia A.N., Kortesidis A., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005, 65:1700-1709.
12. Diamond P., Labrinidis A., Martin S.K., et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 2009, 24:1150-1161.
13. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420.
14. Fujikawa Y., Quinn J.M., Sabokbar A., McGee J.O., Athanasou N.A. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996, 137:4058-4060.
15. Silvestris F., Cafforio P., De Matteo M., Quatraro C., Dammacco F. Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res 2008, 32:611-623.
16. Croucher P.I., Apperley J.F. Bone disease in multiple myeloma. Br J Haematol 1998, 103:902-910.
17. Terpos E., Politou M., Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003, 123:758-769.
18. Cravens P.D., Hayashida K., Davis L.S., Nanki T., Lipsky P.E. Human peripheral blood dendritic cells and monocyte subsets display similar chemokine receptor expression profiles with differential migratory responses. Scand J Immunol 2007, 65:514-524.
19. Hirbe A.C., Morgan E.A., Weilbaecher K.N. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?. Curr Pharm Des 2010, 16:1284-1290.
20. Azab A.K., Runnels J.M., Pitsillides C., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
21. Alsayed Y., Ngo H., Runnels J., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109:2708-2717.
22. Han X., Sterling H., Chen Y., et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 2000, 275:37984-37992.
23. Jourdan M., Moreaux J., Vos J.D., et al. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 2007, 138:160-168.
24. Moreaux J., Hose D., Jourdan M., et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 2007, 92:803-811.
25. Dhodapkar K.M., Barbuto S., Matthews P., et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008, 112:2878-2885.
26. Abe M., Hiura K., Wilde J., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104:2484-2491.
27. Nakashima T., Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009, 29:555-567.
28. Alnaeeli M., Park J., Mahamed D., Penninger J.M., Teng Y.T. Dendritic cells at the osteo-immune interface: implications for inflammation-induced bone loss. J Bone Miner Res 2007, 22:775-780.
29. Maitra R., Follenzi A., Yaghoobian A., et al. Dendritic cell-mediated in vivo bone resorption. J Immunol 2010, 185:1485-1491.
30. McKenna H.J., Stocking K.L., Miller R.E., et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000, 95:3489-3497.
31. Alnaeeli M., Penninger J.M., Teng Y.T. Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells. J Immunol 2006, 177:3314-3326.
32. Leibbrandt A., Penninger J.M. Novel functions of RANK(L) signaling in the immune system. Adv Exp Med Biol 2010, 658:77-94.
33. Sezer O., Heider U., Jakob C., Eucker J., Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002, 20:353-354.
34. Wakkach A., Mansour A., Dacquin R., et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008, 112:5074-5083.
35. Brown E.J., Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001, 11:130-135.
36. Wittrant Y., Theoleyre S., Chipoy C., et al. RANKL/RANK/OPG:new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004, 1704:49-57.